INTRODUCTION
============

The metabolic syndrome has been known to acquire by sedentary lifestyle and calorie rich eating habit. Various metabolic factors may lead to development of life strengthening diseases such as cardiovascular disease, type 2 diabetes, dyslipidemia, and hypertension ([@b45-jer-16-1-27]). Although adult-onset diseases may solely occur without the metabolic factors, the risk for the co-occurrence has been known to increase by several folds with the existing metabolic factors ([@b43-jer-16-1-27]). The most common definitions used to define metabolic syndrome were reported by the World Health Organization (WHO), European Group for Study of Insulin Resistance, National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), International Diabetes Federation (IDF), and Joint Interim Societies (JIS). The metabolic syndrome was defined by basically similar components that included terms. For example, WHO used components such as impaired fasting glucose, impaired glucose tolerance, homeostatic model assessment for insulin resistance, obesity, dyslipidemia, hypertension, waist circumference, and blood pressure as criteria. The NCEP ATP III used components such as fasting triglyceride, fasting high-density lipoprotein, fasting blood glucose as criteria for prevalence of metabolic syndrome ([@b38-jer-16-1-27]).

The member states of the Gulf Cooperation Council (GCC) include Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Recently, the prevalence of the type II diabetes mellitus and related adult-onset disorders have reported to be high in the GCC countries. Several publications reported that four out of six countries of the GCC countries are among the top 10 countries with the greatest prevalence rate for adult-onset type 2 diabetes and cardiovascular diseases ([@b7-jer-16-1-27]; [@b39-jer-16-1-27]; [@b45-jer-16-1-27]). The rapidly increasing rate of the adult-onset chronic complications such as type 2 diabetes and cardiovascular diseases have been related to the changes in the environment and lifestyle that lead to sedentary lifestyle and consumption of food high in calorie ([@b41-jer-16-1-27]). Despite various studies on the prevalence of metabolic syndrome in the GCC countries, the overall report on the metabolic syndrome in the GCC countries is scarce. Therefore, this report was conducted to provide the evidence-based prevalence rate of metabolic syndrome in the GCC area through meta-analysis. Providing evidence- based prevalence rate of the metabolic syndrome in the GCC area could contribute fundamental foundation for developing scientifically supportive evidence for the metabolic syndrome prevention campaign.

MATERIALS AND METHODS
=====================

This study is a systemic review prepared by the meta-analysis based on the guidelines provided by the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis protocol) ([@b44-jer-16-1-27]; [@b49-jer-16-1-27]).

Data sources and search phrases
-------------------------------

In order to obtain evidence-based study results on the prevalence rate for the metabolic syndrome, electronic literature searches were conducted on the web-based database sites such as the PubMed database, Google Scholar, and Web of Science collection. Only the English-language research articles with the nation-wide or population-based subjects were gathered for this study. The initial data collection was conducted without filtering for time. Specific search terms or phrases were used to find the articles. The search phrases included "prevalence of metabolic syndrome in middle east," "prevalence of metabolic syndrome in Arab," "prevalence of metabolic syndrome," "name of country," and "metabolic syndrome."

Article selection procedure
---------------------------

After the initial gathering procedure, the selected articles were considered for inclusion based on the following inclusion and exclusion criteria. This study used broad inclusion criteria to provide comprehensive systemic reviews of the topic.

First, the articles were considered for inclusion if the articles were original research studies and reported on the prevalence rate for the metabolic syndrome. There were no restrictions on the study type unless the articles are review articles. Cohort and cross-sectional studies were also included. Geographic regions such as urban or rural regions were not excluding criteria. The studies on specific clinical complications such as diabetes, acute coronary syndrome, ovary syndrome, or hypertension were excluded from the study. In addition, the studies that did not deal with the prevalence of metabolic syndrome as the major factor were also not included in this study. In the initial selection phase, the studies were selected based on the key terms and phrases. During the second phase, the studies were reviewed for the title and abstract for exclusion. Finally, initially selected articles were screen and reviewed based on the full text for the final exclusion and inclusion process.

Data extraction
---------------

Information on the authors, year of publication, country of origin, sample size, gender and age of the subjects, and study design (case-control, cross-sectional or prospective cohort), metabolic syndrome identification criteria, prevalence of metabolic syndrome, and adjustment variables were obtained from the selected articles. Regarding the considerable factors and expected heterogeneity.

The random-effect model was applied for the analysis of data to obtain the expected heterogeneity and the considerable factors. The Cochran Q-test was utilized to estimate the heterogeneity between the selected studies.

Data synthesis and statistical analysis
---------------------------------------

The management and edition of data, estimation of standard error, and pooled mean effect size were estimated using Comprehensive Meta-Analysis Software (CMA) ver. 2.0 (Biostat, Englewood, NJ, USA). The pooled estimate of the prevalence rates was determined by the definitions on the metabolic syndrome provided by the ATP III, IDF, WHO, and JIS. Finally, the weighted average prevalence rates with 95% confidence interval (CI) for the selected studies were obtained by calculating the fixed effects and random effects of the meta-analysis.

RESULTS
=======

One hundred thirty-two articles were retrieved on the prevalence or metabolic syndrome in the GCC countries through extensive search process online. After through inclusion and exclusion procedures, duplications and irrelevant articles were excluded. After reviewing the title and abstracts, 56 articles were selected for full-text screening. After the full article reviewing, seven articles were excluded due to chronic diseases, three articles were excluded since they were conducted on the subjects that were not of the GCC countries, and five were excluded for being review articles. Therefore, among 132 articles, 37 articles were selected as the final articles for the systematic review. The selection processes for the articles are shown in [Fig. 1](#f1-jer-16-1-27){ref-type="fig"}.

Within 37 articles, 53 different studies were identified and included for the review. Among 53 studies, 19 were published before the year 2009 and 35 were published in the year 2010 or later. Different criteria were used to diagnose metabolic syndrome in the selected studies. Fifteen studies used the criteria proposed by the NCEP ATP III for diagnosing the metabolic syndrome. Eight studies used the criteria by the IDF and 13 studies used the criteria by both NCEP ATP III and IDF. One study used the criteria by NCEP ATP III and WHO and another study used the criteria by NCEP ATP III, IDF, and JIS ([Table 1](#t1-jer-16-1-27){ref-type="table"}). The metabolic syndrome prevalence rate is also shown as a forest plot for in [Fig. 2](#f2-jer-16-1-27){ref-type="fig"}.

[Tables 2](#t2-jer-16-1-27){ref-type="table"} and [3](#t3-jer-16-1-27){ref-type="table"} show the pooled estimates for the prevalence rates of the metabolic syndrome in each country and the overall pooled estimated, respectively. The prevalence rates of the metabolic syndrome in Oman was 0.25 (95% CI, 0.19--0.31), UAE was 0.39 (95% CI, 0.34--0.42), Saudi was 0.28 (95% CI, 0.24--0.33), Kuwait was 0.22 (95% CI, 0.17--0.27), and Qatar was 0.26 (95% CI, 0.18--0.37). Moreover, the pooled prevalence rates of the metabolic syndrome were estimated for the subgroups of studies ([Table 4](#t4-jer-16-1-27){ref-type="table"}). The random pooled samples of the studies reported before 2009 and after 2010 showed the metabolic syndrome prevalence rates of 0.28 (95% CI, 0.24--0.32) and 0.27 (95% CI, 0.23--0.32), respectively.

Twenty-nine studies used the ATP III definition and the prevalence rate in the random pooled estimate was 0.25 (95% CI, 0.22--0.28). Ninety studies used the IDF definition and prevalence rate in the random pooled estimate was 0.28 (95% CI, 0.21--0.36). Three studies used both the ATP III and IDF and their prevalence rate in the random pooled estimate was 0.38 (95% CI, 0.35--0.40). One study used the JIS definition and its prevalence rate in the random pooled estimate was 0.28 (95% CI, 0.22--0.36). Finally, the last one study used the WHO definition and the prevalence rate in the random pooled estimate was 0.39 (95% CI, 0.39--0.45).

Regarding the effects of the adjustment on the random pooled estimates, six adjusted studies showed pooled for prevalence rate by the random effect of 0.28 (95% CI, 0.16--0.32). Forty-seven nonadjusted studies showed pooled prevalence by the random effect of 0.28 (95% CI, 0.25--0.31).

DISCUSSION
==========

This study was conducted to observe the prevalence rate of metabolic syndrome in the GCC countries. In this meta-analysis review, 54 studies and 99,599 subjects were analyzed for the prevalence of metabolic syndrome. Overall, the pooled estimate of the metabolic syndrome prevalence rate in GCC was 0.28 (95% CI, 0.25--0.31). Such metabolic syndrome prevalence rate in the GCC region was greater than that of the other regions such as Latin American, Europe, Africa, and Asia. That is, the observed prevalence rate of the metabolic syndrome in the GCC countries such as was observably higher than other countries worldwide. For example, a systematic review of the countries in the Latin America region showed the metabolic syndrome prevalence rate of 24.9% with the ATP III's metabolic syndrome definition ([@b42-jer-16-1-27]). A combined prospective cohort study on the prevalence rate of the metabolic syndrome reported of 15.0% in Europe with the WHO's metabolic syndrome definition ([@b37-jer-16-1-27]).

The prevalence rates of metabolic syndrome in the Sub-Saharan African regions range from 0% to 7.3% ([@b32-jer-16-1-27]). A systematic review that reported the prevalence rates in the Asia-pacific region was 11.9% and 49.0% according to the definitions by ATP III and modified ATP III, respectively ([@b45-jer-16-1-27]). On the other hand, the prevalence rates reported by the national survey in the United States were 35% and 39% according to the definitions by the ATP III and IDF, respectively ([@b33-jer-16-1-27]). Therefore, the prevalence rate for the metabolic syndrome was high in comparison to some of the regions such as Africa or Asia while still lower than the regions such as the United States.

Over the past few decades, many of the GCC countries have experienced rapid wealth and corresponding urbanization. Such changes have led to a sedentary lifestyle by the general population due to rapid increase in the usage of motored vehicles for commuting. In addition, the working environment and facilities have changed to promote reduction in physical activity. The dietary patterns also changed in association with the environmental changes to promote inactivity and corresponding adult-onset diseases ([@b24-jer-16-1-27]). Conditions such as the infrastructure of the urban areas with scarce sidewalks or parks, hot arid climate, and conservative social culture restrict physical activity in the Gulf region ([@b24-jer-16-1-27]).

Although a vast amount of databases and articles were reviewed with detailed inclusion and exclusion criteria for the final selection limitations exist. Since a significant amount of regional reports were prepared in the native language, non-English articles could not be included in this study. The local studies that represent the regional information may provide more detailed input on the prevalence rate.

However, this is the first meta-analysis report on the prevalence ate of the metabolic syndrome in the GCC countries to our knowledge. This report may provide supportive information to prepare for the measures to intervene to prevent and control the onset of metabolic syndrome in the GCC region. It may assist to manage the morbidity and mortality rate related to adult-onset complications.
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###### 

Characteristics of the reviewed studies

  Country   Study                      Type of study               Published year   Sample size (person)   Metsdefinition                Mets prevalence rate (%)   Adjustments
  --------- -------------------------- --------------------------- ---------------- ---------------------- ----------------------------- -------------------------- -------------
  Oman      Al-Lawati et al.           Cross-sectional             2003             1,419                  ATP III                       17.0 (crude)               
                                                                                                                                         21.0 (adjust)              Age
            Al-Shafaee et al.          Cross-sectional             2008             281                    ATP III                       45.9                       
            El-Aty et al.              Cross-sectional             2014             3,137                  ATP III                       23.6                       Age
            Al-barwani et al.          Cross-sectional             2008             392                    IDF                           28.0                       
                                                                                                           ATP III                       21.0                       
                                                                                                                                                                    
  UAE       Khthir and Espina          Cross-sectional             2014             575                    ATP III                       22.0                       
            Hajat and Shather          Cross-sectional             2012             760                    IDF                           48.7                       
                                                                                                           ATP III                       50.3                       
            Malik and Razig            Cross-sectional             2008             4,097                  IDF                           40.5                       
                                                                                                           ATP III                       39.6                       
                                                                                                                                                                    
  Saudi     Al-Sarraj et al.           Cross-sectional             2008             309                    ATP III                       25.2                       
            Al-Sarraj et al.           Cross-sectional (obesity)   2010             227                    ATP III                       40.4                       
            Haroun et al.              Cross-sectional             2018             591                    IDF                           4.9                        
            Rouzi and Ardawi           Cross-sectional             2009             580                    ATP III                       33.4                       
            Bahijri et al.             Cross-sectional             2013             233                    IDF                           18.9                       
                                                                                                           ATP III                       16.7                       
            Al-Qahtani and Imtiaz      Cross-sectional             2005             1,079                  ATP III                       20.0                       Age
            Aljohani                   Cross-sectional             2014             4,406                  IDF                           28.3                       
            Al-Nozha et al.            Cross-sectional             2005             17,293                 ATP III                       41.4 (crude)               
                                                                                                                                         39.3 (adjust)              Age
            Al-Qahtani et al.          Cross-sectional             2006             2,577                  IDF                           16.1                       Age
                                                                                                           ATP III                       13.6                       Age
            Barrimah et al.            Cross-sectional             2011             560                    ATP III                       31.4                       
            Taha et al.                Cross-sectional             2009             37                     ATP III                       29.7                       
            Alzahrani et al.           Cross-sectional             2012             600                    ATP III                       21.0                       
            Al-Agha et al.             Cross-sectional             2012             387                    ATP III                       14.3                       
            Al-Daghri et al.           Cross-sectional             2013             185                    IDF                           39.0                       
            AboGazalah and AlReshidi   Cross-sectional             2016             250                    ATP III                       36.0                       
                                                                                                           WHO                           39.1                       
            Alswat et al.              Cross-sectional             2016             313                    IDF                           38.4                       
            Aljabri et al.             Cross-sectional (obesity)   2018a            1,526                  IDF                           69.5                       
            Al-Rubeaan et al.          Cross-sectional             2018             12,126                 ATP III/IDF                   39.8                       
            Aljabri et al.             Cross-sectional             2018b            2,810                  IDF                           64.6                       
            Saeed                      Cross-sectional             2019             1,354a                 IDF                           12.0                       
                                                                                                                                                                    
  Kuwait    Badr et al.                Cross-sectional             2007             434                    ATP III                       18.0                       
            Al-Isa et al.              Cross-sectional             2010             431                    IDF                           14.8                       
            Al Zenki et al.            Cross-sectional             2012             1,830                  IDF/ATP III (WC\>102/85 cm)   36.1                       
            Al-Isa                     Cross-sectional             2013             303                    IDF                           11.7                       
                                                                                                           ATP III (modified)            9.8                        
            Roshdy                     Cross-sectional             2011             153                    JIS                           28.1                       
                                                                                                           IDF                           26.1                       
                                                                                                           ATP III                       18.3                       
            Al Rashdan and Al Nesef    Cross-sectional             2010             2,280                  ATP III                       24.8                       
                                                                                                           IDF                           36.2                       
            Boodai et al.              Cross-sectional             2014             80                     ATP III                       30.0                       
                                                                                                           IDF                           21.3                       
                                                                                                                                                                    
  Qatar     Bener et al.               Cross-sectional             2009             1,024                  ATP II                        26.5                       
                                                                                                           IDF                           33.7                       
            Bener et al.               Cross-sectional             2014             1,552                  ATP III                       10.3                       
            Al-Thani et al.            Cross-sectional             2016             2,496                  IDF/ATP III                   37.0                       
            Hammoudeh et al.           Cross-sectional             2018             226                    ATP III                       27.4                       
                                                                                                           IDF                           32.7                       

ATP III, Adult Treatment Panel III; IDF, International Diabetes Foundation; WHO, World Health Organization; JIS, Joint Interim Societies; WC, waist circumference.

###### 

Pooled estimations of the metabolic syndrome prevalence rate by country

  Country   No. of studies   Sample size   Pooled prevalence   95% Confidence interval   *P*-value
  --------- ---------------- ------------- ------------------- ------------------------- ----------------------------------------------------
  Oman      6                7,040         0.25                0.19--0.31                \<0.01[\*](#tfn2-jer-16-1-27){ref-type="table-fn"}
  UAE       5                10,289        0.39                0.34--0.45                \<0.01[\*](#tfn2-jer-16-1-27){ref-type="table-fn"}
  Saudi     24               67,796        0.28                0.24--0.33                \<0.01[\*](#tfn2-jer-16-1-27){ref-type="table-fn"}
  Kuwait    12               8,480         0.22                0.17--0.27                \<0.01[\*](#tfn2-jer-16-1-27){ref-type="table-fn"}
  Qatar     7                5,994         0.29                0.25--0.34                \<0.01[\*](#tfn2-jer-16-1-27){ref-type="table-fn"}

*P*\<0.05.

###### 

Overall pooled estimation of the metabolic syndrome prevalence rate

  Model    No. of studies   Sample size   Pooled prevalence   95% Confidence interval   *P*-value
  -------- ---------------- ------------- ------------------- ------------------------- ----------------------------------------------------
  Fixed    54               99,599        0.37                0.36--0.37                \<0.01[\*](#tfn3-jer-16-1-27){ref-type="table-fn"}
  Random   54               99,599        0.28                0.25--0.31                \<0.01[\*](#tfn3-jer-16-1-27){ref-type="table-fn"}

*P*\<0.05.

###### 

Summary of the main results of the reviewed articles

  Variable                No. of studies   Sample size   Effect sizes (95% CI)     Effect sizes (95% CI)      *P*-value
  ----------------------- ---------------- ------------- ------------------------- -------------------------- ----------------------------------------------------
                                                         Fixed pooled prevalence   Random pooled prevalence   
                                                                                                              
  Year of study                                                                                               
   2003--2009             19               56,884        0.37 (0.36--0.37)         0.28 (0.24--0.32)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
   2009--2019             35               42,715        0.37 (0.36--0.37)         0.28 (0.24--0.32)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
                                                                                                              
  Diagnostic criteria                                                                                         
   ATP III                29               56,815        0.36 (0.35--0.36)         0.25 (0.22--0.28)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
   IDF                    20               25,929        0.37 (0.36--0.37)         0.30 (0.23 --0.38)         \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
   ATP III/IDF            3                16,452        0.39 (0.38--0.40)         0.38 (0.35--0.40)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
   JIS                    1                153           0.28 (0.22--0.36)         0.28 (0.22--0.36)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
   WHO                    1                250           0.39 (0.33--0.45)         0.39 (0.33--0.45)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
                                                                                                              
  Adjustment                                                                                                  
   Age and sex adjusted   6                31,409        0.33 (0.32--0.33)         0.23 (0.16--0.32)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}
   Nonadjusted            48               36,997        0.38 (0.38--0.39)         0.28 (0.26--0.32)          \<0.01[\*](#tfn5-jer-16-1-27){ref-type="table-fn"}

CI, confidence interval; ATP III, Adult Treatment Panel III; IDF, International Diabetes Foundation; JIS, Joint Interim Societies; WHO, World Health Organization.

*P*\<0.05.
